Abbott Laboratories (ABT) Stock
NYSEABT has an Alpha Score of 37 out of 100 (weak), computed on Oct 28, 2026 from 3 of 4 sub-scores. 50 members of Congress disclosed 125 trades in ABT since 2014: 66 purchases and 58 sales, most recently Pete Sessions (sale, Oct 2, 2026). 8 of the hedge funds AlphaScala tracks reported ABT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $780.11M. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 31.2 and its net margin 11.7% (key statistics as of Oct 22, 2026).
What is ABT's Alpha Score?
How it works →Alpha Score of 37 reflects weak overall profile with weak momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Abbott Laboratories (ABT)?
Most recent: Pete Sessions (sale, Oct 2, 2026); records start Jun 10, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Pete Sessions R-TX · House | 2026-10-02 | sale | $50k – $100k |
| Gil Cisneros D-CA · House | 2026-09-18 | purchase | $1k – $15k |
| Rich McCormick R-GA · House | 2026-07-30 | sale | $1k – $15k |
| Mike Kelly R-PA · House | 2026-07-17 | sale | $1k – $15k |
| Rick Allen R-GA · House | 2026-07-14 | sale | $15k – $50k |
| Rick Larsen D-WA · House | 2026-07-08 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-06-16 | purchase | $1k – $15k |
| Rich McCormick R-GA · House | 2026-06-12 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded ABT, with filing lags →Which hedge funds own ABT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 8.60M | $780.11M | +349% |
| Marshall Wace | 5.54M | $502.92M | +176% |
| Millennium Management Israel Englander | 3.60M | $326.66M | +172% |
| Point72 Steve Cohen | 1.55M | $140.82M | NEW |
| D.E. Shaw David Shaw | 1.46M | $132.26M | -72% |
| Renaissance Technologies Jim Simons (founder) | 686K | $62.28M | -45% |
| Bridgewater Associates Ray Dalio | 60K | $5.42M | -49% |
| Soros Fund Management George Soros (founder) | 45K | $4.06M | n/a |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Abbott Laboratories insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | Mccoy John A. Jr. | VICE PRESIDENT AND CONTROLLER | SELL | 27 | $3K |
| Aug 25, 26 | Ford Robert B | CHAIRMAN AND CEO | SELL | 218.5K | $25.3M |
| Aug 25, 26 | Ford Robert B | CHAIRMAN AND CEO | SELL | 180.3K | $20.9M |
| Aug 11, 26 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | SELL | 5.8K | $643K |
| Mar 2, 26 | Shroff Eric | Senior Vice President | SELL | 709 | $82K |
| Mar 2, 26 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | SELL | 885 | $102K |
| Mar 2, 26 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | SELL | 1.1K | $132K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are ABT's key statistics?
Key statistics as of Oct 22, 2026
How does ABT's valuation compare with the Healthcare sector?
| Metric | ABT | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 31.2 | 27.1 | 97 |
| Net margin | 11.65% | 5.48% | 139 |
| Return on equity | 10.52% | 6.84% | 158 |
| Dividend yield (payers) | 1.98% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
What did Abbott Laboratories's latest SEC filings say?
Latest 2Abbott Laboratories Completes Acquisition of Exact Sciences Corporation for Cash Consideration
On March 23, 2026, Abbott Laboratories finalized its acquisition of Exact Sciences Corporation. The transaction was executed pursuant to the Agreement and Plan of Merger originally dated November 19, 2025. Under the terms of the agreement, a wholly owned subsidiary of Abbott, Badger Merger Sub I, Inc., merged with and into Exact Sciences. As a result of the merger, Exact Sciences now operates as a direct, wholly owned subsidiary of Abbott Laboratories. Shareholders of Exact Sciences common stock received $105.00 in cash for each share held immediately prior to the effective time of the merger, excluding certain shares as defined in the agreement. The filing confirms the completion of the merger and incorporates the original merger agreement and a press release regarding the closing as exhibits.
- ›Abbott Laboratories completed the acquisition of Exact Sciences Corporation on March 23, 2026.
- ›Exact Sciences is now a direct, wholly owned subsidiary of Abbott Laboratories.
- ›Exact Sciences shareholders received $105.00 in cash per share of common stock.
- ›The transaction was executed under the terms of the November 19, 2025, merger agreement.
Abbott Laboratories Issues $20 Billion in Senior Notes to Fund Exact Sciences Acquisition
On March 9, 2026, Abbott Laboratories completed a public offering of $20 billion in aggregate principal amount of senior notes. The issuance consists of eight series of notes with varying maturities, ranging from floating rate notes due in 2029 to fixed-rate notes maturing as late as 2066. The offering was conducted pursuant to a pricing agreement dated February 23, 2026, with underwriters including Morgan Stanley, Barclays, BofA Securities, and J.P. Morgan Securities. Abbott intends to use the net proceeds from this offering, alongside cash on hand and potential additional borrowings, to finance its previously announced acquisition of Exact Sciences Corporation. The funds are earmarked for the merger consideration, the repayment of certain Exact Sciences indebtedness, transaction-related fees, and general corporate purposes. The notes include a special mandatory redemption provision. If the acquisition of Exact Sciences is not consummated by the specified "End Date" (generally February 17, 2027, or a later agreed-upon date) or if Abbott notifies the trustee that it will not pursue the acquisition, the company is required to redeem the outstanding notes at 101% of their aggregate principal amount, plus accrued and unpaid interest.
- ›Completed $20 billion senior notes offering across eight tranches.
- ›Proceeds designated for the acquisition of Exact Sciences Corporation.
- ›Includes special mandatory redemption at 101% if the acquisition fails to close.
- ›Funds will also cover repayment of Exact Sciences debt and transaction expenses.
- ›Notes issued under a shelf registration statement effective February 23, 2026.
ABT price chart
Powered by TradingViewWhat does Abbott Laboratories do?
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of health care products worldwide. It operates across four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, addressing needs from chronic disease management to acute diagnostics. The company offers generic pharmaceuticals treating conditions such as pancreatic exocrine insufficiency, irritable bowel syndrome, dyslipidemia, hypertension, hypothyroidism, pain, fever, inflammation, and migraine, alongside anti-infectives, influenza vaccines, and gastrointestinal regulators. Notable products include cardiovascular devices like pacemakers and stents, diabetes management tools such as continuous glucose monitors, pediatric and adult nutritional formulas, and advanced diagnostic equipment like immunoassays and point-of-care testing kits. With approximately 114,000 employees and a history dating back to 1888, Abbott Laboratories generates the majority of its sales outside the United States, playing a pivotal role in advancing medical innovation, improving patient outcomes, and supporting global health initiatives through its extensive reach in consumer, institutional, and professional markets.